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Background. Cannabis and tobacco have contrasting cognitive effects. Smoking cannabis with tobacco is prevalent in
many countries and although this may well influence cognitive and mental health outcomes, the possibility has rarely
been investigated in human experimental psychopharmacological research.
Method. The individual and interactive effects of cannabis and tobacco were evaluated in 24 non-dependent cannabis
and tobacco smokers in a randomized, placebo-controlled, double-blind, 2 (cannabis, placebo) × 2 (tobacco, placebo)
crossover design. Verbal memory (prose recall), working memory (WM) performance including maintenance, manipu-
lation and attention (N-back), psychotomimetic, subjective and cardiovascular measures were recorded on each of four
sessions.
Results. Cannabis alone impaired verbal memory. A priori contrasts indicated that tobacco offset the effects of cannabis
on delayed recall. However, this was not supported by linear mixed model analysis. Cannabis load-dependently
impaired WM. By contrast, tobacco improved WM across all load levels. The acute psychotomimetic effects and ratings
of ‘stoned’ and ‘dizzy’ induced by cannabis were not altered by tobacco. Cannabis and tobacco had independent effects
on increasing heart rate and interacting effects on increasing diastolic blood pressure.
Conclusions. Relative to placebo, acute cannabis impaired verbal memory and WM. Tobacco enhanced performance on
WM, independently of cannabis. Moreover, we found some preliminary evidence that tobacco may offset the effects of
cannabis on delayed, but not immediate, verbal recall. In contrast, the psychotomimetic and subjective effects of cannabis
were unaffected by tobacco co-administration. By reducing the cognitive impairment from cannabis, tobacco co-
administration may perpetuate use despite adverse health consequences.
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Introduction
Cannabis and tobacco, two of the world’s most com-
monly used drugs, are frequently co-administered
together in ‘joints’ or ‘spliffs’ (Hindocha et al. 2016).
Delta-9-tetrahydrocannabinol (THC) and nicotine,
respectively are these drugs primary psychoactive
components. Cannabinoid receptors (CB1R) and nico-
tine acetylcholine receptors (nAChRs) are both densely
populated in the hippocampus and the amygdala, sug-
gesting a potential neurobiological overlap (Herkenham
et al. 1990; Picciotto et al. 2000) for the effects of these
two drugs on memory. This is evident behaviourally
as THC and nicotine have opposite effects on memory
and cognition in humans with THC impairing and
nicotine facilitating performance (Gray et al. 1996;
Levin & Simon, 1998; Curran et al. 2002; D’Souza et al.
2004; Levin et al. 2006; Morrison et al. 2009; Heishman
et al. 2010; Bossong et al. 2012). Preclinical data suggest
a relationship between the endocannabinoid system
and the cholinergic system. Full or partial agonists of
the CB1R, including THC, increase nicotine conditioned
place preference (Valjent et al. 2002) and self-
administration (Gamaleddin et al. 2012) whereas
antagonists at this receptor (e.g. rimonabant) decrease
these behaviours (Le Foll & Goldberg, 2004; Cohen
et al. 2005; Forget et al. 2005; Shoaib, 2008). Further nico-
tine and THC both interact with mesolimbic dopamin-
ergic pathways potentially modulating reward-related
processes in addiction (Rowell et al. 1987; Fernandez-
Ruiz et al. 2010).
Acutely, cannabis produces a profile of cognitive
impairment, similar to that associated with schizophre-
nia, and particularly in the realms of working and epi-
sodic memory (Fletcher & Honey, 2006; Broyd et al.
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2016; Curran et al. 2016). Deficits in episodic memory
are some of the most robust findings reported (Crane
et al. 2013). Dose-dependent (Hart et al. 2010) effects
of THC on working memory are also consistently
reported (Hunault et al. 2009; Ramaekers et al. 2009)
and are specifically related to the manipulation rather
than the maintenance of information. Nicotine, in
contrast, improves memory in both smokers and
non-smokers (Heishman et al. 2010). It has been
hypothesised that tobacco might compensate for
some of the negative effects of cannabis (Rabin &
George, 2015). In support of this, individuals smoking
cannabis and cigarettes have less episodic memory
impairment when drug free compared with cannabis
users alone (Schuster et al. 2015), but experience
worse cognitive withdrawal symptoms from tobacco
in regards to episodic and working memory
(Jacobsen et al. 2007). Moreover, an ecological moment-
ary assessment study found that when cannabis and
tobacco are combined, working memory performance
was better in comparison with cannabis alone
(Schuster et al. 2016). However, to our knowledge, no
controlled studies have examined whether tobacco
can offset the cognitive impairing effects of cannabis.
Importantly, epidemiological research has impli-
cated both cannabis and tobacco as independent risk
factors for psychosis (Moore et al. 2007; Gurillo et al.
2015). It is clear that both cigarette smoking and prob-
lematic cannabis use are highly prevalent in people
with schizophrenia in epidemiological research (De
Leon & Diaz, 2005; Koskinen et al. 2010). However, it
can be extremely challenging to dissociate the role of
cannabis from tobacco in these studies due to the
high co-occurrence of their use both i.e. cannabis
users are more likely to smoke cigarettes, and cannabis
and tobacco are often combined into joints and smoked
together (Gage et al. 2014). Acutely, cannabis/THC
induces psychotic-like effects, including paranoia,
disorganised thinking and hallucinations. However,
there is no such experimental evidence that nicotine/
tobacco induces or exacerbates psychotic- symptoms
acutely. One study investigated the acute effect of a
nicotine patch on cannabis induced psychotomimetic
effects (using the Addiction Research Center Inventory:
LSD subscale) where nicotine had no effect on THC
(Penetar et al. 2005). However, this study lacks the eco-
logical administration method of ‘joints’ and did not
use a scale specific to the psychotomimetic drug effects
(Mason et al. 2008). Thus, given the high prevalence of
use of cannabis and tobacco, it is necessary to understand
the interactive effects on psychotic-like symptoms
induced by cannabis.
This study, therefore, aimed to investigate the indi-
vidual and combined effects of cannabis and tobacco
on episodic and working memory, and psychotic-like
experiences. We hypothesised that tobacco would
acutely counteract the negative effects of cannabis on
working and episodic memory and will directly test
with an a priori comparison of the combination of canna-
bis + tobacco and cannabis alone. We also hypothesised
that cannabis would increase psychotic-like symptoms;
how nicotine would influence these was exploratory
given the dearth of previous relevant research.
Methods and materials
Design and participants
A randomised double-blind, placebo-controlled, four-
way, crossover trial was used to evaluate the acute
effects of cannabis and tobacco, both alone and com-
bined (Table 1). Participants attended four sessions,
separated by at least 1-week washout (as this is 5 3
times elimination half-life of THC) (D’Souza et al.
2008; Hindocha et al. 2015). Washout of nicotine was
confirmed by Carbon Monoxide (CO) 4 6 (Bedfont
Micro Smokerlyser, Bedfont Scientific Ltd, Bedfont,
UK). Order of treatment was determined by a balanced
Latin square. All participants provided written, in-
formed consent on each occasion. Ethical approval
was given by the UCL Ethics Committee.
Medically and psychiatrically healthy, non-
dependent but experienced, cannabis and tobacco
users were recruited. A flowchart of participant recruit-
ment can be found in the online Supplementary
Materials (see online Supplementary Fig. S2).
Power calculation
Power was informed by a previous four-way crossover
trial examining interactive effects of THC and Canna-
bidiol (CBD) (d = 0.5; based on a t test of THC +CBD
attenuating negative effects of THC (Hindocha et al.
2015)). This estimated a sample size of 24 participants
with complete data would achieve power of d = 0.5 to
Table 1. Cannabis and tobacco doses in the study drug and their
matched placebos (see Fig. 1)
Drug Condition Description
Cannabis Active 66.67 mg Bedrobinol (16.1%
THC and <1% CBD)
Matched
placebo
66.67 mg Placebo (derived from
Bedrocan; 0.07% THC)
Tobacco Active 311 mg Marlboro Red (15.48 mg




311 mg denicotinized tobacco
(Magic 0, 0.04 mg/g nicotine)
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detect such effects with an alpha of 0.05 (G*power ver-
sion 3.1.9.2) (Faul et al. 2007). This was also appropriate
for completely balancing the order of the four treat-
ments completed the study as 24 = 4 factorial.
Inclusion criteria
Inclusion criteria were: (i) age 18–60 years, (ii) regular
(5 once per month and 4 3 times a week) use of can-
nabis and tobacco in joints for the last 6 months, (iii)
self-reported (SR) ability to smoke one whole ‘standard’
joint, (iv) normal or corrected-to-normal vision, (v)
fluent English, (vi) SR abstinence from tobacco, canna-
bis, alcohol and other drugs for5 12 h prior to each ses-
sion, (vii) alveolar CO 4 6 ppm to confirm no recent
smoking on each test day (Cooper & Haney, 2009).
Exclusion criteria were (i) scoring 5 3 on the cannabis
Severity of Dependence Scale (SDS; Gossop et al.
1995), (ii) treatment-seeking for cannabis, tobacco use,
or currently using nicotine replacement therapy or
other cessation pharmacotherapy; (iii) smoking 5 10
cigarettes a day or scoring 5 4 on the Fagerstrom Test
of Nicotine Dependence (FTND; Heatherton et al.
1991) consistent with previous research (Agrawal et al.
2009), (iv) first cigarette smoked within the first 3 h
after waking (to ensure cognitive results were not sim-
ply due to reversal of withdrawal from tobacco (Jarvik
et al. 2000)), (v) significant respiratory, physical or clinic-
ally diagnosed learning disorders, (vi) SR diagnosis of a
psychotic disorder (or a first degree family member
with a psychotic disorder), or substance use disorder,
or (vii) SR use of illicit substance use other than canna-
bis more than once per week.
Drug administration (Fig. 1/Table 1)
We compared the effects of (a) active cannabis + active
tobacco (CAN-TOB) (b) active cannabis + placebo
tobacco (CAN), (c) placebo cannabis + active tobacco
(TOB), (d) placebo cannabis + placebo tobacco (no
active drug) (PLACEBO). Thedose of cannabis specified
in Table 1 was based on previous experimental studies
reporting robust subjective, cardiovascular, psychoto-
mimetic and memory impairing effects (Lawn et al.
2016; Mokrysz et al. 2016). This dose of tobacco reliably
produces peak plasma nicotine levels >20 ng/ml
(Mendelson et al. 2003, 2005) and is similar to a standard
cannabis + tobacco joint (Hunault et al. 2009; VanDer Pol
et al. 2014). Placebo tobacco was the same dose of Very
Low Nicotine (VLN; typically referred to as denicoti-
nized) tobacco (Magic 0; XXII Century Group Ltd).
Procedure
After telephone screening, eligible participants
attended a baseline session involving further screening
and task training and then four experimental sessions.
Each experimental session began with pre-drug Visual
Analogue Scales (VAS), physiological measures and a
CO measurement to check abstinence from smoking.
Participants then listened to a passage of prose and
were required to immediately recall its content (story
1). Drug administration took place immediately after
this (see online Supplementary Materials for full
details on smoking procedure). Thirty-five minutes
after drug administration, participants listened to a
second passage of prose and immediately recalled its
contents (story 2). Delayed recall of story 1 and 2
occurred approximately 55 min after drug administra-
tion. Participants completed the N-back and Psychoto-
mimetic States Inventory (PSI; Mason et al. 2008) at 21
and 45 min, respectively (see the assessment flowchart
online Supplementary Fig. S2). Other tasks that are not
reported here took place in the intervening time.




Participants completed the Beck Depression Inventory
(BDI; Beck et al. 1996), Spielberger State-Trait Anxiety
Inventory (STAI; Spielberger et al. 1970), Schizotypal
Personality Questionnaire (SPQ; Raine, 1991) and a
detailed drug history including questions about
Fig. 1. Drug administration was conducted using ‘joints’,
the most common method of administering cannabis
(Hindocha et al. 2016). ‘Study drug’ region contained a
mixture of 66.67 mg cannabis (active or placebo) and 311 mg
tobacco (active or placebo) dependent on condition (see
Table 1). The ‘placebo tobacco filler’ region contained 311
mg of placebo tobacco at the bottom of the joint (nearest to
the mouth), which was not smoked. This filler was added to
improve compliance with the fixed inhalation procedure
(see online Supplementary Materials), as puff volume
typically decreases towards the end of the joint, probably
due to rising heat (Van Der Pol et al. 2014). The stop line is
the point at which participants stopped smoking the joint,
separating the two regions. It was marked 1 cm after the
‘study drug’ to ensure complete inhalation.
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cannabis and tobacco co-use. CO, heart rate (HR), sys-
tolic and diastolic blood pressure (BP) and subjective
effects were measured pre- (−10) and at 10, 30, 40
and 70 min’ post-drug.
Cognitive measures
The Prose Recall subtest of the Rivermead Behavioral
Memory Test (Wilson et al. 1991) taps episodic mem-
ory. Participants were required to listen to a passage
of prose (a 30 s news bulletin) and recall its contents
both immediately and after a delay. The first story (1)
was heard before drug administration, followed by
immediate recall. The second story (2) was heard 35
min after drug administration. Delayed recall of both
was approximately 55 min after drug administration.
This design was chosen to dissociate drug effects on
encoding from retrieval (Fletcher & Honey, 2006).
Drug effects on encoding would be evidenced by
story 2 (both immediate and delayed) being affected,
but not story 1 (i.e. a drug × story interaction). If
there were drug effects on retrieval, this would be evi-
denced by a difference on delayed, but not immediate,
recall of story 1 (i.e. a drug × story × delay interaction).
Each story contained 21 ‘idea units’ and scoring was
systematic. The primary outcome is the mean number
of idea units recalled. The eight versions were counter-
balanced across drug and design.
A Spatial N-back was used to assess spatial working
memory. Visual stimuli (smiley faces) appeared in one
of six different locations around a central fixation cross
on the computer screen, in a sequential order (Freeman
et al. 2012; Morgan et al. 2014). Participants responded
by pressing a ‘Yes’ or ‘No’ key according to whether (a)
the stimuli appeared in a pre-defined location (zero
back; attentional control), (b) whether the stimulus was
in the same position as the stimulus one before (1-back),
and subsequently, (c) two before (2-back). Four versions
of the task were counterbalanced across drug and design
and reaction time and accuracy were recorded.
Psychotomimetic effects
The Psychotomimetic States Inventory (PSI) (Mason
et al. 2008) was used to assess current schizotypal symp-
toms. It has 48 items and is specifically designed to
measure drug-induced changes in psychotic-like symp-
toms. It has previously been shown to be sensitive to
cannabis-induced psychotomimetic effects and has bet-
ter test-retest reliability than the Clinician Administered
Dissociative States Scale (CADSS; De Simoni et al. 2013).
Statistical analysis
Data were analysed using IBM Statistical Package for
Social Sciences (IBM SPSS version 23). Outliers more
than 2.5 standard deviations (S.D.) from the sample
mean were replaced with a score falling within 2.5 S.D.
Normality was explored using visual inspection of
diagnostic plots. Data for the Prose Recall, N-back
and PSI was analysed using linear mixed models,
which included a random intercept for subjects and
two within subjects factors of drug: Cannabis (placebo;
active) and Tobacco (placebo; active). Additional task-
specific factors of Story (1, 2) and Delay (immediate,
delayed) for the prose recall and Load (0, 1, 2) for
N-back outcomes (correct responses, RT, d′, C). VAS
scores and physiological factors (HR, BP, CO) had
an additional task-specific factor of Time (1 (predrug)
v. 2, 3, 4, 5 (postdrug)). The unstructured variance-
covariance structure was selected following D’Souza
et al. (2012). Interactions were explored via Bonferroni
corrected post-hoc comparisons locally within hypoth-
eses but not across hypotheses (D’Souza et al. 2012).
All descriptive statistics for linearmixedmodels are esti-
mated marginal means and standard error. d′ and C
(N-back)were calculated using signal detection analysis
(Snodgrass & Corwin, 1988). The loglinear approach
was used to account for perfect scores (Hautus, 1995;
Stanislaw & Todorov, 1999). Maintenance was calcu-
lated as 1-back minus 0-back and manipulation as
2-back minus 1 back.
Results
Demographics and drug history
A total of 24 participants (12 women), with a mean ±
S.D. age of 24.46 ± 3.96 completed the study. They had
minimal dependence on cannabis (SDS: 0.67 ± 0.92
(range: 0–3)) and tobacco (FTND: 0.33 ± 0.64 (range:
0–2)). Those who smoked daily (N = 6) reported smok-
ing their first cigarette 5.91 ± 3.01 h after waking.
Baseline questionnaire scores were: STAI trait 35.75 ±
8.60; BDI 6.17 ± 5.82; SPQ 19.14 ± 10.83. Other drug
use apart from alcohol was minimal (see online
Supplementary Table S1).
Assessments
There were no significant pre-drug differences between
the four drug conditions in VAS scores, HR, BP, CO or
Short State Anxiety Inventory (SSAI; Marteau &
Bekker, 1992). There were no significant differences
on time taken or a number of puffs between drug con-
ditions (online Supplementary Table S2).
Prose recall (Fig. 2)
There was a cannabis × story interaction (F1,23 = 18.51,
p < 0.001) and a story × delay interaction (F1,23 = 26.60,
p < 0.001). There were also main effects of cannabis
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(F1,23 = 10.65, p = 0.003) and delay (F1,23 = 107.58,
p < 0.001) but not of tobacco or story. No significant
interaction between cannabis and tobacco emerged
(F1,23 = 0.812, p = 0.317).
The cannabis × story interaction showed poorer
recall following cannabis (M: 7.71, S.E.: 0.63) for story
2 in comparison with placebo (M: 10.44, S.E.: 0.68)
(p < 0.001) but not for story 1 (p = 0.324). Under placebo
cannabis, there was greater recall for story 2 (M: 10.44,
S.E.: 0.68) in comparison with story 1 (M: 8.45, S.E.: 0.51)
(p < 0.001). By contrast, for active cannabis, there was
greater recall on story 1 (M: 8.94, S.E.: 0.62), in compari-
son with story 2 (M: 7.71, S.E.: 0.63) (p = 0.019).
To test our a priori hypothesis that tobacco compen-
sates for the detrimental effect of cannabis on memory
we compared the difference between CAN-TOB on
immediate and delayed recall for story 2 with critical
t tests (Fig. 2a). On immediate recall, there was no dif-
ference (t23 = 1.38, p = 0.182) but on delayed recall,
scores were significantly higher after CAN-TOB com-
pared with CAN; the mean difference was 1.75 idea
units (S.D.: 3.87) (t23 = 2.21, p = 0.037, d = 0.5) (Fig. 2b).
The story × delay interaction showed that story 2 (M:
8.47, S.E.: 0.61) was remembered better than story 1 (M:
7.31, S.E.: 0.61) after the delay (p = 0.007) but there was
no difference for immediate recall (p = 0.360), which
suggests a recency effect. The main effect of cannabis
(M: 8.32, S.E.: 0.56) clearly showed that cannabis
impaired recall in comparison with placebo (M: 9.45,
S.E.: 0.54). The main effect of delay simply showed
delayed recall (M: 7.89, S.E.: 0.58) was poorer than
immediate recall (M: 9.88, S.E.: 0.48).
N-back
Correct responses (Fig. 3a, b)
There was a cannabis × load interaction (F2,23 = 4.82, p =
0.018), which showed that cannabis impaired the 1-
and 2-back but not the zero-back (Fig. 3a; also online
Supplementary Table S3). A main effect of cannabis
(F1,23 = 15.93, p = 0.001), reflected better performance
on placebo than cannabis and a main effect of tobacco
(F1,23 = 4.88, p = 0.037) reflected better performance on
active tobacco (M: 43.77, S.E.: 0.55) than placebo (M:
42.58, S.E.: 0.56) across all load conditions (Fig. 3b). A
main effect of load (F2,23 = 43.42, p < 0.001) reflected bet-
ter performance on 0-back than 1- and 2-back, respect-
ively. No significant interaction between cannabis and
tobacco emerged. The critical a priori t test between
CAN-TOB and CAN on N-back correct responses
across all loads was not significant (p > 0.5).
Signal detection analysis (Fig. 3c, d)
d′: there was a main effect of cannabis (F1,23 = 14.48,
p < 0.001) where it reduced discriminability in compari-
son with placebo (Fig. 3c), a main effect of tobacco
(F1,23 = 8.25, p = 0.009) where tobacco increased discrim-
inability in comparison with placebo (Fig. 3d) and a
main effect of load, (F2,23 = 28.33, p < 0.001). The highest
discriminability was for the 0-back, followed by the
1-back, followed by the 2-back and there were no sign-
ificant interactions. The critical apriori t test between
CAN-TOB and CAN on d′ averaging over all loads
showed a trend towards higher scores with
CAN-TOB in comparison with CAN (t23 = 2.00, p =
0.059, d = 0.47).
Criterion (C): there was a main effect of load (F2,23 =
245.90, p < 0.001) whereby the criterion was higher for
the 0-back (M: 0.50, S.E.: 0.02), followed by the 1-back
(M: −0.04, S.E.: 0.02) and 2-back (M: −0.06, S.E.: 0.03).
Reaction time
There was a cannabis × load interaction (F2,23 = 8.82, p <
0.001), which showed that cannabis impaired the
2-back in comparison with placebo (p = 0.005) but not
the 1-back (p = 0.214) or the 0 back (p = 0.979). There
was a main effect of load (F2,23 = 68.90, p < 0.001),
which showed increasing RT across load. There were
no main effects or interactions with tobacco.
Fig. 2. (a and b) Immediate recall (a) and delayed recall (b) under each drug condition for both story 1 (where encoding was
not intoxicated) and story 2 (where encoding was intoxicated). Under delayed recall, for story 2, we found CAN-TOB in
comparison with CAN, improves delayed recall but this was not the case for immediate recall, therefore suggesting effects on
retrieval of information that had previously been successfully encoded. Error bars show ±S.E.M.
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Manipulation and maintenance
A main effect of cannabis on manipulation (F1,23 = 5.86,
p = 0.024) showed cannabis impaired manipulation
(M: −5.67, S.E.: 1.04) in comparison with placebo
(M: −3.27, S.E.: 0.77); there were no other effects or
interactions. No main effects or interactions emerged
for maintenance.
Psychotomimetic states inventory
A main effect of cannabis (F1,33 = 33.01, p < 0.001)
showed cannabis (M: 32.04, S.E.: 3.53) markedly
increased PSI scores in comparison with placebo (M:
13.85, S.E.: 1.76); there were no other effects or interac-
tions. The same pattern of results emerged when
including PSI subscale as an additional factor.
Schizotypy has previously been found to predict
acute psychotomimetic response to cannabis; therefore,
we added SPQ score as an additional covariate. This
did not reveal any interactions between SPQ score
and drug effect on the PSI.
Physiological measures
Carbon monoxide (Fig. 4a)
There was a main effect of cannabis (F1,161 = 4.32, p =
0.039), which showed that under active cannabis,
participants had a lower CO than under placebo can-
nabis. There was also a main effect of time (F1,161 =
415.49, p < 0.001).
Heart rate (Fig. 4b)
A cannabis × time interaction (F1,161 = 62.88, p < 0.001)
revealed a significant increase on active cannabis, com-
pared with placebo cannabis, post-drug administration
(MDiff: 22.71, S.E.: 2.22, p < 0.001), but no difference pre-
drug. It also revealed an increase between pre-and
post-drug for active cannabis (MDiff: 27.31, S.E.: 2.20,
p < 0.001), but not for placebo cannabis. A tobacco ×
time interaction (F1,161 = 4.49, p = 0.036) revealed a sign-
ificant increase between tobacco and placebo, post-
drug (MDiff: 6.88, S.E.: 2.20; p = 0.002). There was no
difference between tobacco and placebo pre-drug.
Under both placebo and active tobacco, there was an
increase in HR from pre- to post-drug (placebo tobacco
MDiff: 11.53, S.E.: 2.20; p < 0.001, active tobacco MDiff:
18.18, S.E.: 2.20, p < 0.001). There were main effects of
cannabis (F1,161 = 42.73, p < 0.001), tobacco (F1,161 =
5.125, p = 0.025) and time (F1,161 = 89.53, p < 0.001).
Blood pressure (Fig. 4c, d)
For diastolic blood pressure, there was a cannabis ×
tobacco × time interaction (F1,161 = 5.56, p = 0.02). All
Fig. 3. (a–d) Number of correct responses (a & b) and d′ (c & d) for cannabis v. placebo (a & c) and tobacco v. placebo (b & d)
for the N-back. Error bars show ±S.E.M.
Cannabis and tobacco interactions 2713
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291717001222
Downloaded from https://www.cambridge.org/core. Australian Catholic University, on 04 Dec 2019 at 03:23:43, subject to the Cambridge Core terms of use, available at
drugs conditions, with the exception of PLACEBO,
increased diastolic BP from pre- to post- drug. At the
post-drug time point, this manifested in greater dia-
stolic BP under TOB (MDiff: 6.33, S.E.: 1.61, p < 0.001)
and CAN (MDiff: 6.22, S.E.: 1.61, p < 0.001) than
CAN-TOB (MDiff: 1.26, S.E.: 1.61, p = 0.44). There was
also a cannabis × tobacco interaction, which was
explained/subsumed by the above three-way interaction
(F1,161 = 5.70, p = 0.2). Finally, there was a cannabis × time
interaction (F1,161 = 4.64, p = 0.03), which revealed a sign-
ificant that active cannabis increased diastolic blood
pressure, pre- to post-drug (MDiff: 4.51, S.E.: 1.13; p
< 0.001), but not under placebo cannabis. There was
also a main effect of time (F1,161 = 11.91, p = 0.001).
There were no other main effects or interaction. For
systolic blood pressure, a cannabis × tobacco inter-
action (F1,161 = 4.65, p = 0.03) emerged however pair-
wise comparisons revealed no significant differences




There was a cannabis × time interaction (F1,161 = 84.59,
p < 0.001), which revealed a significant increase pre-
to post-drug for active cannabis (MDiff: 4.95, S.E.:
0.31; p < 0.001) and for placebo cannabis to a lesser
extent (MDiff: 0.91, S.E.: 0.31; p = 0.004). There was no
difference between placebo and active cannabis pre-
drug, however, there was a significant difference post-
drug (MDiff: 4.02, S.E.: 0.31; p < 0.001). There was also a
main effect of cannabis (F1,161 = 82.85, p < 0.001) and a
main effect of time (F1,161 = 178.25, p < 0.001). There
were no main effects or interactions with tobacco.
Dizzy (Fig. 4f)
There was a cannabis × time interaction (F1,161 = 17.07,
p < 0.001), which revealed a significant increase pre-
to post-drug for active cannabis (MDiff: 2.41, S.E.:
Fig. 4. (a–f) carbon monoxide (CO), cardiovascular (heart rate (HR), systolic and diastolic blood pressure (mmHg)) and
self-reported effects for stoned and dizzy for all time points before (T1) and after (T2–T5) each drug administration. Error bars
show ±S.E.M.
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0.27; p < 0.001) and for placebo cannabis to a lesser
extent (MDiff: 0.83, S.E.: 0.27; p = 0.002). Pre-drug,
there was no difference between active and placebo
cannabis (p = 0.817) however active cannabis increased
‘dizzy’ ratings post-drug (MDiff: 1.51, S.E.: 0.27, p <
0.001). There were significant main effects of cannabis
(F1,161 = 17.46, p < 0.001), and time (F1,23 = 29.15, p <
0.001). No tobacco × time or cannabis × tobacco × time
interactions emerged.
Discussion
In the first study to investigate the acute interaction
between cannabis and tobacco using a controlled ran-
domised crossover design with an ecological method
of drug administration, we found that cannabis
impairs episodic memory. We found preliminary evi-
dence to support our hypothesis that tobacco would
offset the effects of cannabis on verbal recall.
However, this finding emerged for delayed but not
immediate recall, and was not supported by linear
mixed model analysis, so should be treated with cau-
tion until replicated. When active tobacco is combined
with active cannabis the impairment in delayed recall
is slightly attenuated in comparison with cannabis
alone. In regards to WM, we saw opposite independ-
ent effects whereby cannabis was detrimental to WM,
and tobacco improved working memory performance.
We also found that tobacco had no effect on
cannabis-induced psychotic-like experiences. In
regards to physiological effects, all drug conditions
apart from the placebo increased diastolic BP post-
drug. Diastolic BP was lower under mixed cannabis
and tobacco than either cannabis alone or tobacco
alone. The biological mechanisms of this effect are
uncertain, but warrant further investigation, as mixed
tobacco and cannabis is the primary route of self-
administration. Both cannabis and tobacco had inde-
pendent effects on HR, with cannabis producing greater
increases in HR than tobacco. Tobacco did not influence
ratings of ‘stoned’ or ‘dizzy’, which are classic
cannabis-induced effects. Taken together, we foundmin-
imal evidence for interactive effects of cannabis and
tobacco in a controlled 2 × 2 design with an ecological
method of drug administration. However, our results
tentatively suggest that the common practise of adding
tobacco to cannabis in joints (Hindocha et al. 2016)
may reduce cognitive impairment from cannabis, but
does not influence users’ psychotic-like experiences or
subjective experience of the drug.
Previous research has shown that cannabis acutely
induces robust cognitive deficits in working and epi-
sodic memory (Curran et al. 2002; D’Souza et al. 2004;
Morrison et al. 2009; Bossong et al. 2012). Tobacco has
been shown to have the opposite effect on the same
cognitive constructs but with much smaller effect
sizes (Heishman et al. 2010) and both drugs act on
receptors that densely populate the hippocampus.
The a priori comparison on a prose recall task show,
although there was no cannabis × tobacco interaction
in the linear mixed model analysis, participants per-
formed significantly better after cannabis and tobacco
combined than cannabis alone for delayed recall
(mean difference: 1.75 idea units) but not for immedi-
ate recall. These findings are similar to Englund et al.
(2013) who found that THC-induced impairments in
delayed but not immediate recall were attenuated by
pre-treatment of CBD (Englund et al. 2013). Together,
the prose recall and N-back results suggest that
tobacco/nicotine increased attentional resources that
may be involved in trying to recall information
that had previously been encoding correctly. The
delayed recall task is more difficult and requires
greater attentional resources than the immediate recall
task, and these results are in line with the general
improvement effect found on the N-back. These results
are also consistent with a recent study of chronic can-
nabis use, which found a cannabis × tobacco interaction
for delayed recall. However, this effect was only evi-
dent among those who consistently smoked cigarettes
(>100 per year) in comparison with those who sporad-
ically smoked cigarettes (<100 per year) (Schuster et al.
2015). However, this study did not use a controlled
design, used a relatively arbitrary cut-off for cigarettes
and could not investigate adding tobacco to cannabis
in the same product.
In regards to WM, we found the detrimental effect of
cannabis (in comparison with placebo) on the N-back
were load-dependent i.e. impairment increased with
load, and was selective to manipulation (not mainten-
ance). By contrast, facilitative effects of tobacco on cor-
rect responses and discriminability were
load-independent, and did not influence manipulation
or maintenance, perhaps suggesting that tobacco
effects are purely on attention. This is consistent with
previous function magnetic resonance imaging
(fMRI) research showing nicotine altered activity in a
neural network associated with task monitoring and
attention (Kumari et al. 2003). Our results are consistent
with a recent naturalistic study (Schuster et al. 2016),
which used a 40-s WM task on mobile phones and
found WM was impaired by cannabis, improved by
tobacco, and when used simultaneously, participants
showed no impairment. Moreover, both Schuster
et al. (2016) and the present study did not find evidence
for a cannabis × tobacco interaction for WM perform-
ance. In the present study a priori comparisons between
cannabis + tobacco and cannabis alone were only
approaching significance for d′. Our findings
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complement those of Schuster et al. (2016) and provide
impetus for further investigation into the interactive
effects of cannabis and tobacco on cognition. This
study may also provide some mechanistic insights
into memory and why both substances may be
co-administered however, it would be essential to rep-
licate this finding in another controlled study. One
potential consequence of nicotinic attenuation of the
effects of THC on memory may be that it feeds into
continued drug taking as certain acute adverse effects
are diminished. These results may have relevance to
dual diagnosis populations, for whom rates of both
cigarette and cannabis (and tobacco), use are high, pre-
senting an important line of future research.
Tobacco had no effect on feeling ‘stoned’ or ‘dizzy’
despite this strongly-held belief that adding tobacco
to cannabis increases positive subjective effects
(Amos et al. 2004). Although tobacco potentially offset
some of the impairing effect of cannabis on memory,
this occurred in absence of any positive subjective
effects. This is in contrast to previous human experi-
mental research, which found that nicotine patch
pre-treatment increased reports of feeling stimulated
and an amphetamine-like feelings scale (Penetar et al.
2005). However, we found a cannabis × tobacco inter-
action on diastolic BP, and independent effects of can-
nabis and tobacco on heart rate, which suggest that
combining the two, increases the cardiovascular risk
of smoking cannabis (for diastolic BP, the combined
was lower than cannabis alone and tobacco alone,
however this does not negate the increase in diastolic
BP). There is a clear public health implication here,
suggesting that smoking cannabis with tobacco does
not improve the subjective effects of cannabis, and
makes it more harmful to one’s physical health.
In relation to the PSI results, we found no modifica-
tion of PSI scores by either tobacco alone or in combin-
ation with cannabis. This corresponds to research that
finds nicotine also fails to attenuate ketamine-induced
psychotic-like experiences and cognitive deficits
(D’Souza et al. 2012). In recent epidemiological studies,
tobacco and cannabis have been shown to independ-
ently predict the rate of psychotic-like experiences (Van
Gastel et al. 2013; Gage et al. 2014). However, the rela-
tionship between cannabis, tobacco, and psychosis is
complicated given tobacco and cannabis are so strongly
correlated. These findings do not negate a possible long-
term effect of tobacco on psychosis. However, they sug-
gest that such an association is less biologically plausible
than for cannabis, as evidenced by acute drug effects.
Strengths and limitations
Strengths of this study include a large sample
size (informed by an a priori power calculation), its
double-blind, randomized, double-placebo-controlled,
crossover design, and use of well-validated tasks.
Furthermore, we selected participants with minimal
dependence on tobacco (and cannabis), which suggests
that nicotinic facilitation was not purely due to the
reversal of withdrawal effects. We used the PSI,
which has better test-retest reliability than other scales
designed to tap psychotic like effects (De Simoni et al.
2013). Pharmacokinetics (PK)/pharmacodynamics(PD)
were not measured so we are unable to comment on
temporal changes that occur. For example, previous
research has shown that nicotine increases the length
of the cannabis effect in some participants (Penetar
et al. 2005). Furthermore, nicotine effects reduce
quickly after administration (Mendelson et al. 2003,
2005) in comparison with the cannabis effect and we
were not able to conduct multiple dosing studies or
ideally, an intravenous study (D’Souza et al. 2012)
however the short-testing window was designed to
capture nicotine’s effects. Finally, given the novelty of
the research, with multiple statistical comparisons
study of cannabis and tobacco, we would suggest
that these findings be treated with caution until
replicated.
Conclusions
In conclusion, this study found that cannabis impaired
working and episodic memory. We found preliminary
evidence that tobacco co-administration may offset the
effects of cannabis on episodic memory. We charac-
terised the acute subjective and cardiovascular effects
of cannabis and tobacco administered together through
a shared route of administration (i.e. joints) and found
that these effects were similar to cannabis alone. There
was no effect of tobacco on cannabis induced psychoto-
mimetic effects.
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